AAO makes case for OPT for Medicare patients
Washington, DC-The Medicare Coverage Advisory Committee has voted overwhelmingly in favor of making ocular photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) available as a valid and important treatment for treating AMD in select patients with subfoveal choroidal neovascularization (CNV) with occult but no classic CNV.
Recent Videos
Related Content
